Last reviewed · How we verify
NCT06472128: NAVIGATE
Novel Digital Application for Patients With Acute Leukemia
NA trial testing DREAMLAND in Relapsed Adult Acute Myeloid Leukemia in 200 participants. Currently enrolling.
30 April 2029
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 200 |
| Start date | 21 October 2024 |
| Primary completion | 30 April 2029 |
| Estimated completion | 30 April 2030 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- DREAMLAND
- VITAL WELLNESS
Conditions studied
- Relapsed Adult Acute Myeloid Leukemia — all drugs for Relapsed Adult Acute Myeloid Leukemia →
- Primary Refractory Acute Myeloid Leukemia — all drugs for Primary Refractory Acute Myeloid Leukemia →
- High Risk Acute Myeloid Leukemia — all drugs for High Risk Acute Myeloid Leukemia →
Sponsor
Massachusetts General Hospital
Who can join
Adults 18 to 120, any sex, with Relapsed Adult Acute Myeloid Leukemia or Primary Refractory Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06472128
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of DREAMLAND
Trials testing the same drug.
- NCT05501171 — Psychological Mobile App for Patients With AML · NA · terminated
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06472128 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 10 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06472128.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing